Candesartan: A new-generation angiotensin II AT1 receptor blocker: Pharmacology, antihypertensive efficacy, renal function, and renoprotection

Journal of the American Society of Nephrology

Volumn 10, Issue 1 SUPPL. 11, 1999, Pages

  Morsing, Peter ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b Pharmacology CV   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTOREGULATION; DRUG EFFICACY; DRUG HALF LIFE; GENE EXPRESSION REGULATION; HEMODYNAMICS; HORMONAL REGULATION; HYPERTENSION; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0032904060     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351: 1755-1762, 1998
2. Fletcher AE, Palmer AJ, Bulpitt CJ: Cough with angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens 12[Suppl 2]: S43-S47, 1994
3. Johnston CI: Angiotensin receptor antagonists: Focus on losartan. Lancet 346: 1403-1407, 1995
4. Kubo K, Kohara Y, Imamiya E, Sugiura Y, Inada Y, Furukawa Y, Nishikawa K, Naka T: Nonpeptide angiotensin II receptor antagonists, synthesis and biological activity of benzimidazole-carboxylic acids. J Med Chem 36: 2182-2195, 1993
5. Hübner R, Högemann AM, Sunzel M, Riddell JG: Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 11[Suppl 2]: S19-S25, 1997
6. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benz-imidazole-7- carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylate (TCV-116). J Pharmacol Exp Ther 266: 114-120, 1993
7. Nishikawa K, Inada Y, Shibouta Y, Wada T, Ojima M, Kubo K, Naka T: Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116. Blood Press Suppl 5: 7-14, 1994
8. Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new non-peptide AII antagonist. Biochem Pharmacol 46: 311-318, 1993
9. 1 receptor. Eur J Pharmacol 319: 137-146, 1997
10. Abrahamsson T, Karp L, Brandt-Eliassson U, Morsing P, Renberg L, Sjöquist P-O: Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: A comparison with irbesartan, losartan and its active metabolite (EXP 3174) [Abstract]. Am J Hypertens 4: 37A, 1998
11. Morsing P, Brandt-Eliassson U, Renberg L, Abrahamsson T: Candesartan, an insurmountable antagonist of angiotensin II mediated contractile effects in isolated vascular preparations: A comparison with irbesartan, losartan and its active metabolite (EXP 3174) [Abstract]. Am J Hypertens 4: 37A, 1998
12. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265: 826-834, 1993
13. Champion HC, Kadowitz PJ: Analysis of the effects of candesartan in the mesenteric vascular bed of the cat. Hypertension 30: 1260-1266, 1997
14. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21, 1995
15. Heuer HJ, Schondorfer G, Hogemann AM: Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 11[Suppl 2]: S55-S56, 1997
16. Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7- carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 268: 1540-1547, 1994
17. Ito K, Shiomi M, Kito G: Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 18: 69-75, 1995
18. Wada T, Sanada T, Ojima M, Kanagawa R, Nishikawa K, Inada Y: Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Hypertens Res 19: 247-254, 1996
19. O'Sullivan JB, Black MJ, Bertram JF, Bobik A: Cardiovascular hypertrophy in one-kidney, one-clip renal hypertensive rats: A role for angiotensin II? J Hypertens 12: 1163-1170, 1994
20. Ideishi M, Miura S-I, Sakai T, Maeda H, Kinoshita A, Sasaguri M, Jimi S, Arakawa K: Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl Rats. Blood Press 3[Suppl 5]: 99-104, 1994
21. Elmfeldt D, George M, Hubner R, Olofsson B: Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 11[Suppl 2]: S49-S53, 1997
22. Andersson OK, Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 7: 53-59, 1998
23. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25: 1345-1350, 1995
24. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19: 1079-1099, 1997
25. Stier CT Jr, Adler LA, Levine S, Chander PN: Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl 11: S37-S42, 1993
26. Byyny RL: Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: Results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Blood Press 5[Suppl 2]: 71-77, 1996
27. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg Al, Nelson EB: Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 155: 405-411, 1995
28. Weber MA, Neutel JM, Smith DHG: Controlling blood pressure throughout the day: Issues in testing a new anti-hypertensive agent. J Hum Hypertens 9[Suppl 5]: S29-S35, 1995
29. Azizi M, Nicolet L, Chatellier G, Guyene TT, Hempenius J, Ménard J: Is the differentiation of AT1 receptor antagonists feasible in normotensive volunteers? [Abstract] J Hypertens 15[Suppl 4]: S116, 1997
30. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641-649, 1995
31. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 11[Suppl 2]: S27-S28, 1997
32. Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS: Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 6: 35-43, 1997
33. Chiu AT, McCall DE, Price WA Jr, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PB: In vitro pharmacology of DuP 753. Am J Hypertens 4: 282S-287S, 1991
34. Seikaly MG, Arant BS Jr, Seney FD Jr: Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 86: 1352-1357, 1990
35. Braam B, Mitchell KD, Fox J, Navar LG: Proximal tubular secretion of angiotensin II in rats. Am J Physiol 264: F891-F898, 1993
36. Kawabata M, Takabatake T, Ohta H, Nakamura S, Kara H, Ohta K, Takakuwa H, Han WH, Kobayashi K: Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press Suppl 5: 117-121, 1994
37. Fridman K, Andersson OK, Wysocki M, Friberg P: Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 11 [Suppl 2]: S43-S44, 1997
38. Kito G, Ito K, Shiomi M: General pharmacological properties of the new angiotensin II receptor antagonist (±)-1-(Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidiazole-7-carboxylate. Part II. Effect on cardiovascular system and renal functions. Arzneim-Forsch 46: 1-6, 1996
39. 1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol 274: F940-F945, 1998
40. Haddad G, Amiri F, Garcia R: Modulation of renal glomerular angiotensin II receptors by ACE inhibition and AT1 receptor antagonism. Regul Pept 68: 111-117, 1997
41. Takishita S, Muratani H, Sesoko S, Teruya H, Tozawa M, Fukiyama K, Inada Y: Short-term effects of angiotensin II blockade on renal blood flow and sympathetic activity in awake rats. Hypertension 24: 445-450, 1994
42. Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y: Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats. Jpn J Pharmacol 73: 185-190, 1997
43. Li XC, Widdop RE: Angiotensin type I receptor antagonists CV-11974 and EXP 3174 cause selective renal vasodilation in conscious spontaneously hypertensive rats. Clin Sci 91: 147-154, 1996
44. Li XC, Widdop RE: Regional hemodynamic effects of the AT1 receptor antagonist CV-11974 in conscious renal hypertensive rats. Hypertension 26: 989-997, 1995
45. 1 receptor blockade with candesartan. J Am Soc Nephrol 1999, this supplement
46. Gross V, Lippoldt A, Schneider W, Luft FC: Effect of captopril and angiotensin II receptor blockade on pressure natriuresis in transgenic TGR (mRen-2)27 rats. Hypertension 26: 471-479, 1995
47. Inscho EW, Imig JD, Deichmann PC, Cook AK: Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II infused rats. J Am Soc Nephrol 1999, this supplement
48. Jover B, Mimran A: Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: Effects on renal function. J Hypertens 12[Suppl 9]: S3-S9, 1994
49. Mizuno K, Niimura S, Tani M, Saito I, Sanada H, Takahashi M, Okazaki K, Yamaguchi M, Fukuchi S: Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci 51: 183-187, 1992
50. Wada T, Inada Y, Sanada T, Ojima M, Shibouta Y, Noda M, Nishikawa K: Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone. Eur J Pharmacol 253: 27-34, 1994
51. Ogihara T, Nagano M, Higaki J, Kohara K, Mikami H: Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects. J Cardiovasc Pharmacol 26: 490-494, 1995
52. Inada Y, Wada T, Ojima M, Sanada T, Shibouta Y, Kanagawa R, Ishimura Y, Fujisawa Y, Nishikawa K: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19: 1079-1099, 1997
53. Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y: Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats. Jpn J Pharmacol 73: 185-190, 1997
54. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 46: 1346-1358, 1994
55. Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T: Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest 65: 61-66, 1991
56. Horikoshi S, Ray PE, Adler SH, Kopp JP, Koide H, Klotman PE: Interleukin-6 stimulates fibronectin expression by human mesangial cells [Abstract]. J Am Soc Nephrol 2: 576, 1991
57. Moriyama T, Fujibayashi M, Fujiwara Y, Kaneko T, Xia C, Imai E, Kamada T, Ando A, Ueda N: Angiotensin II stimulates interleukin-6 release from cultured mesangial cells. J Am Soc Nephrol 6: 95-101, 1995
58. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura T, Chatani F, Iwao H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195-204, 1994
59. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13: 113-122, 1995
60. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T: Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 21: 975-979, 1993
61. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 12[Suppl 9]: S11-S16, 1994
62. Kanno Y, Okada H, Suzuki H, Ikenaga H, Saruta T: Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats. Blood Press 3[Suppl 5]: 67-70, 1994
63. Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T: Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 26: 564-569, 1995
64. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47: 935-944, 1995
65. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309, 1992
66. Hamaguchi A, Kim S, Wanibuchi H, Iwao H: Angiotensin II and calcium blockers prevent glomerular phenotypic changes in remnant kidney model. J Am Soc Nephrol 7: 687-693, 1996
67. Shibouta Y, Chatani F, Ishimura Y, Sanada T, Ohta M, Inada Y, Nishikawa K: TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int 49: S115-S118, 1996
68. Yayama K, Matsui T, Takano M, Hayashi K, Nagamatsu T, Suzuki Y, Okamoto H: Activation of the renin angiotensin system in anti-glomerular basement membrane antibody-induced glomerulonephritis. Biol Pharm Bull 18: 411-415, 1995
69. Yayama K, Makino J, Takano M, Okamoto H: Role of angiotensin II in the transforming growth factor-β1 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritis. Biol Pharm Bull 18: 687-690, 1995